Dynavax Technologies Corporation (DVAX) : The short interest in Dynavax Technologies Corporation (DVAX) has changed with an increase of 53,027 shares and the open interest is 0.7%. From 7,164,526 short positions on Jul 29, 2016, the shorts increased to 7,217,553 shares by August 15, 2016. There are 11 more days left for the expiry and the daily trading volume of the stock is 667,912 shares. The total interest of shorts is 19.2% of the shares available to the public. The short interest information was released on Wednesday Aug 24th after the market close.
Dynavax Technologies Corporation (NASDAQ:DVAX): The stock opened at $16.82 on Wednesday but the bulls could not build on the opening and the stock topped out at $17.50 for the day. The stock traded down to $15.95 during the day, due to lack of any buying support eventually closed down at $16.04 with a loss of -4.81% for the day. The stock had closed at $16.85 on the previous day. The total traded volume was 822,964 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the Officer (Vice President) of DYNAVAX TECHNOLOGIES CORP, Janssen Robert had purchased shares worth of $19,863 in a transaction dated on June 28, 2016. A total of 1,452 shares were purchased at a price of $13.68 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.